Bustling biotech pushes Cambridge, MA surge in VC deals, dollars

Even a casual observer of the biotech industry would know that Cambridge, MA, has seen a booming biotech sector fueled with a steady stream of venture deals. And in a year when venture deals and dollars have been considerably constricted overall, the Cambridge hub has continued to hum with VC activity.

CB Insights took a look at the venture numbers and concluded that Cambridge was eclipsing some of the suburban communities. Over the past four quarters close to a billion dollars in new venture cash has flowed into Cambridge companies through 122 deals. That's a jump of 5% in funds and 27% in deals.

Boston, meanwhile, has been holding its own while Waltham and Woburn have been bringing up the end of the venture parade. "Within the state, there appears to be a shift happening as cities like Cambridge and Boston steal venture capital share from other destinations like Waltham and Woburn," reports CB Insights.

How do they stack up? Boston has seen $541 million of funding and 63 deals over the past year, roughly half of what Cambridge has seen. Those numbers demonstrate "Cambridge's dominance over Boston." Massachusetts overall is the number two state in the U.S. for venture cash.

- here's the venture report from CB Insights

Special Reports: Q3 biotech venture investing makes a boisterous leap | The Top 15 Biotech Venture Investments in H1 2012

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.